Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 6, 2008
Reporting Period: Single event date (June 6, 2008)
Oramed Pharmaceuticals Inc., a Nevada corporation, filed this report to disclose a Regulation FD event regarding the presentation of clinical research data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a scientific disclosure and does not contain financial statements or operational financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing details a specific event: the selection of an abstract for presentation at a major scientific conference.
Guidance, Outlook, and Management Commentary
- Event: Oramed, in conjunction with the Diabetes Unit at Hadassah University Hospital, was selected to display an abstract at the American Diabetes Association's Scientific Sessions Conference.
- Event Dates: June 6-10, 2008, in San Francisco, California.
- Abstract Title: "Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects."
- Exhibit: A copy of the abstract is included as Exhibit 99.1.
- Legal Disclaimer: The information contained in this report and its exhibits is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the full text of the abstract titled "Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin in Healthy Subjects" (Exhibit 99.1) to understand the specific clinical data presented.
- Confirm the attendance and presentation details at the American Diabetes Association's Scientific Sessions Conference held June 6-10, 2008.
- Review subsequent filings for any financial impact or strategic decisions resulting from the conference presentation.